Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BEVACIZUMAB Cause Incorrect product administration duration? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Incorrect product administration duration have been filed in association with BEVACIZUMAB (JOBEVNE). This represents 0.0% of all adverse event reports for BEVACIZUMAB.

5
Reports of Incorrect product administration duration with BEVACIZUMAB
0.0%
of all BEVACIZUMAB reports
0
Deaths
3
Hospitalizations

How Dangerous Is Incorrect product administration duration From BEVACIZUMAB?

Of the 5 reports, 3 (60.0%) required hospitalization.

Is Incorrect product administration duration Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BEVACIZUMAB. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does BEVACIZUMAB Cause?

Off label use (12,094) Death (8,493) Diarrhoea (4,911) Disease progression (4,653) Fatigue (4,572) Nausea (4,357) Hypertension (4,309) Anaemia (3,221) Vomiting (3,193) Neutropenia (2,875)

What Other Drugs Cause Incorrect product administration duration?

ETONOGESTREL (3,974) POLYETHYLENE GLYCOL 3350 (2,129) NIRMATRELVIR\RITONAVIR (744) DOCOSANOL (634) LANSOPRAZOLE (564) LOPERAMIDE (543) NAPROXEN (499) INSULIN LISPRO (479) DICLOFENAC (362) OMEPRAZOLE (302)

Which BEVACIZUMAB Alternatives Have Lower Incorrect product administration duration Risk?

BEVACIZUMAB vs BEVACIZUMAB-AWWB BEVACIZUMAB vs BEVACIZUMAB-BVZR BEVACIZUMAB vs BEVACIZUMAB-MALY BEVACIZUMAB vs BEXAROTENE BEVACIZUMAB vs BEYAZ

Related Pages

BEVACIZUMAB Full Profile All Incorrect product administration duration Reports All Drugs Causing Incorrect product administration duration BEVACIZUMAB Demographics